Cargando…
The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial
The Normal Hematocrit Trial (NHT) was the largest trial of epoetin randomizing 1265 hemodialysis patients with cardiac disease to lower (9–11 g/dl) or higher (13–15 g/dl) hemoglobin (Hgb), hypothesizing that higher Hgb would reduce mortality, and improve survival and quality of life. The trial was t...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388517/ https://www.ncbi.nlm.nih.gov/pubmed/22437411 http://dx.doi.org/10.1038/ki.2012.76 |